Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer

• Verfasst von: Triggiani, Luca [VerfasserIn]
• Verfasst von: Lohr, Frank [VerfasserIn]
• Titel: Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer
• Titelzusatz: new evidence from a multicentric study
• Verf.angabe: Luca Triggiani, Filippo Alongi, Michela Buglione, Beatrice Detti, Riccardo Santoni, Alessio Bruni, Ernesto Maranzano, Frank Lohr, Rolando D’Angelillo, Alessandro Magli, Alberto Bonetta, Rosario Mazzola, Nadia Pasinetti, Giulio Francolini, Gianluca Ingrosso, Fabio Trippa, Sergio Fersino, Paolo Borghetti, Paolo Ghirardelli and Stefano Maria Magrini
• E-Jahr: 2017
• Jahr: 06 June 2017
• Umfang: 6 S.
• Fussnoten: Gesehen am 26.10.2018
• Titel Quelle: Enthalten in: British journal of cancer
• Ort Quelle: Edinburgh : Nature Publ. Group, 1999
• Jahr Quelle: 2017
• Band/Heft Quelle: 116(2017), 12, Seite 1520-1525
• ISSN Quelle: 1532-1827
• DOI: doi:10.1038/bjc.2017.103
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1582349177

Abstract

Background:The aim of the present study is to evaluate the impact of metastases-directed stereotactic body radiotherapy in two groups of oligometastatic prostate cancer (PC) patients: oligorecurrent PC and oligoprogressive castration-resistant PC (oligo-CRPC).Methods:Inclusion criteria of the present multicentre retrospective analysis were: (1) oligorecurrent PC, defined as the presence of 1-3 lesions (bone or nodes) detected with choline positron emission tomography or CT plus bone scan following biochemical recurrence; (2) oligo-CRPC, defined as metastases (bone or nodes) detected after a prostatic-specific antigen rise during androgen deprivation therapy (ADT). Primary end points were: distant progression-free survival (DPFS) and ADT-free survival in oligorecurrent PC patients; DPFS and second-line systemic treatment-free survival in oligo-CRPC patients.Results:About 100 patients with oligorecurrent PC (139 lesions) and 41 with oligo-CRPC (70 lesions), treated between March 2010 and April 2016, were analysed. After a median follow-up of 20.4 months, in the oligorecurrent group 1- and 2-year DPFS were 64.4 and 43%. The rate of LC was 92.8% at 2 years. At a median follow-up of 23.4 months, in the oligo-CRPC group 1- and 2-year DPFS were 43.2 and 21.6%. Limitations include the retrospective design.Conclusions:Stereotactic body radiotherapy seems to be a useful treatment both for oligorecurrent and oligo-CRPC.